- The Oxford vaccine against the coronavirus has produced an immune response in the elderly and young, they announced this Monday.
- Adverse reactions to the Oxford vaccine were lower among the elderly, authorities noted.
- The Oxford vaccine report offers more hope in the global fight against coronavirus.
Hopeful announcements. Oxford’s coronavirus vaccine has produced an immune response among the elderly and young.
The news agency Reuters reported that the coronavirus vaccine being developed by the University of Oxford has produced an immune response in both the elderly and the young and adverse reactions were lower among the elderly, British drug manufacturer AstraZeneca Plc indicated on Monday.
A vaccine that works is seen as a major game changer in the battle against the new coronavirus, which has killed more than 1.15 million people, hit the global economy and shut down normal life around the world. .
The Financial Times newspaper reported that the vaccine, developed by Oxford and AstraZeneca, activates protective antibodies and T cells in older age groups.
That media named two people familiar with the promising find.
Immunogenicity blood tests performed on a subset of older participants echo data published in July that showed the vaccine elicited “robust immune responses” in a group of healthy adults ages 18 to 55, the newspaper reported.
“It is encouraging to see that immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the severity of COVID-19 disease is greatest,” an AstraZeneca spokesperson told Reuters.
“The results further build the body of evidence for AZD1222’s safety and immunogenicity,” the spokesperson noted.
Details of the finding are expected to be published shortly in a clinical journal, said the Financial Times, which did not name which publication it would be.